Literature DB >> 24731000

Pathophysiology and diagnosis of Guillain-Barré syndrome - challenges and needs.

Sambit Dash1, Aparna R Pai, Ullas Kamath, Pragna Rao.   

Abstract

Guillain-Barré syndrome (GBS) is an autoimmune polyneuropathy which presents with acute onset and rapid progression of flaccid, hyporeflexi quadriparesis. Both sensory and autonomic nerve involvement is seen. GBS has various subtypes that vary in their pathophysiology. The pathogenesis involves an immune response triggered by a preceding event which may be an infection, immunisation or surgical procedure. Clinical diagnosis has been largely the primary diagnosing criterion for GBS along with electrodiagnosis, which has several pitfalls and is supported by ancillary testing of cerebrospinal fluid (CSF) analysis and Nerve Conduction Studies. Measurement of anti-ganglioside antibodies is also an effective tool in its diagnosis. Further understanding of pathophysiology and better diagnostic methods are required for better management of GBS.

Entities:  

Keywords:  Campylobacter jejuni; anti-ganglioside antibodies; autoimmunity; electrodiagnosis; molecular mimicry

Mesh:

Year:  2014        PMID: 24731000     DOI: 10.3109/00207454.2014.913588

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  8 in total

1.  Cloning, Expression, Purification, Regulation, and Subcellular Localization of a Mini-protein from Campylobacter jejuni.

Authors:  Soumeya Aliouane; Jean-Marie Pagès; Jean-Michel Bolla
Journal:  Curr Microbiol       Date:  2016-01-11       Impact factor: 2.188

2.  T-box transcription factor 21 is expressed in terminal Schwann cells at the neuromuscular junction.

Authors:  Albina Jablonka-Shariff; Curtis Broberg; Rachel Rios; Alison K Snyder-Warwick
Journal:  Muscle Nerve       Date:  2021-05-12       Impact factor: 3.852

3.  cj0371: A Novel Virulence-Associated Gene of Campylobacter jejuni.

Authors:  Xueqing Du; Nan Wang; Fangzhe Ren; Hong Tang; Xinan Jiao; Jinlin Huang
Journal:  Front Microbiol       Date:  2016-07-14       Impact factor: 5.640

Review 4.  Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review).

Authors:  Adina Stoian; Georgiana Șerban; Zoltan Bajko; Sebastian Andone; Oana Mosora; Adrian Bălașa
Journal:  Exp Ther Med       Date:  2021-01-25       Impact factor: 2.447

Review 5.  B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells.

Authors:  Carlo G Bonasia; Wayel H Abdulahad; Abraham Rutgers; Peter Heeringa; Nicolaas A Bos
Journal:  Cells       Date:  2021-05-13       Impact factor: 6.600

Review 6.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

7.  Clinical Features and Outcome of Guillain-Barré Syndrome in Children.

Authors:  Jafar Nasiri; Mohamadreza Ghazavi; Omid Yaghini; Mohamad Chaldavi
Journal:  Iran J Child Neurol       Date:  2018

8.  Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillain-Barré syndrome.

Authors:  Mária Péter; Wanda Török; Anna Petrovics-Balog; László Vígh; László Vécsei; Gábor Balogh
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.